The Cost Savings Potential of Biosimilar Drugs in the United States
The U.S. Food and Drug Administration is expected to release regulations outlining lower-cost approval requirements for so-called biosimilar drugs. This Perspective combines prior research and recent data to estimate cost savings in the U.S. market.